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Abstract  
Staphylococcus aureus (S. aureus) is a gram-positive bacterium causing skin infections. Today many 
S. aureus strains are methicillin resistant and are therefore called methicillin resistant S. aureus 
(MRSA). Since MRSA cannot be treated with methicillin, alternative treatments are examined today. 
The purpose of this project is to examine the possibility of boosting the immune system. This was 
done through a literature review examining AKB-4924, lipopolysaccharides (LPS) and S. aureus in 
general. The effect of LPS-induced macrophages on S. aureus was examined through an experiment 
where four different samples were made. One sample contained only macrophages while the three 
others were infected with S. aureus. Of these three infected samples, one was not treated with LPS, 
while two others were treated with LPS for 2 and 24 hours respectively. The harvest times of the 
samples were 0.5, 2 and 24 hours after infection. The amount of S. aureus of each sample was 
counted, and thus the influence of LPS could be examined.  
The conclusion of this project is that S. aureus secretes proteins like Staphylokinase, the chemotaxis 
inhibitory protein of Staphylococcus aureus, staphylococcal complement inhibitor, and 
staphylococcal superantigen-like proteins (SSLs), like SSL3, SSL5, and SSL7. These might impair the 
complement system and the TLR signaling, and thereby phagocytosis and lysis of S. aureus. In order 
to boost the immune system these proteins might be ideal targets. Furthermore, AKB-4924 and LPS 
can possibly be used to boost the immune system. Though, our results did not indicate that LPS 
boost the bacterial killing by the macrophages. Thus, further studies are needed in order to conclude 
whether the immune system can be boosted.   
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Resume 
Staphylococcus aureus (S. aureus) er en gram-positiv bakterie, som forårsager hudinfektioner. I dag 
er mange af S. aureus stammerne methicillin-resistente og derfor betegnes de methicillin-resistente 
S. aureus (MRSA). Da MRSA ikke kan behandles med methicillin, undersøges der i dag for alternative 
behandlinger. Formålet med dette projekt er at undersøge muligheden for at fremme 
immunforsvaret. Dette blev gjort gennem et litteraturstudie, hvor AKB-4924, lipopolysakkarider 
(LPS) og S. aureus generelt set blev undersøgt. Effekten af LPS-inducerede makrofager på S. aureus 
blev undersøgt gennem et eksperiment, hvor der var lavet fire forskellige prøver. Den ene prøve 
indeholdte kun makrofager, hvorimod de andre tre var inficeret med S. aureus. Af disse tre 
inficerede prøver, fik en ikke tilsat LPS, imens de to sidste fik tilsat LPS i henholdsvis 2 og 24 
timer.  Høsttiderne for prøverne var 0,5, 2 og 24 timer efter infektionen. Mængden af S. aureus blev 
for hver prøve talt, og dermed kunne LPS’s effekt bestemmes. Det blev konkluderet, at S. aureus 
udskiller proteinerne Staphylokinase, chemotaxis inhibitory protein of Staphylococcus aureus, 
staphylococcal complement inhibitor og staphylococcal superantigen-like proteins (SSLs), såsom 
SSL3, SSL5 og SSL7. Disse proteiner forringer muligvis komplementsystemet og TLR signaleringen og 
herved også fagocytose og lysering af S. aureus. For at fremme immunforsvaret vil disse proteiner 
muligvis være ideelle kandidater for målrettet behandling. Yderligere kan AKB-4924 og LPS muligvis 
blive brugt til at fremme immunforsvaret. Vores resultater indikerede derimod at LPS ikke 
stimulerer makrofagerne til at slå S. aureus ihjel. Der kræves derfor flere studier for at konkludere 
om immunforsvaret kan blive fremmet.  
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Introduction 
In 1880 Sir Alexander Ogston discovered the bacteria Staphylococcus aureus (S. aureus), which can 
cause different types of infections like pneumonia and endocarditis (van Belkum et al., 2009).  S. 
aureus is a gram-positive bacterium and a naturally part of the human flora (Bager et al., 2015). 
Penicillin could be used to treat almost all strains of S. aureus in the beginning of the 1940s, but S. 
aureus developed resistance against penicillin around the year of 1942, and in the early 1960s 
almost all hospital strains of S. aureus had developed resistance (Deurenberg & Stobberingh, 2008; 
Lowy, 2003; Duerden et al., 2015). S. aureus produces the enzyme β-lactamase when exposed to 
antibiotics like penicillin, which inactivates the effects of penicillin (Lowy, 2003). This knowledge 
lead in 1961 to the development of another type of penicillin, methicillin, which is able to resist the 
β-lactamase. Shortly after methicillin’s introduction, methicillin resistant S. aureus (MRSA) strains 
were observed (Duerden et al., 2015; Lowy, 2003). A report made in 2014 by Danish Antimicrobial 
Resistance Monitoring and Research Program showed collected data of MRSA instances in humans. 
They reported 57 incidents of MRSA blood-infections in Denmark (Bager et al., 2015). A similar 
report published in 2012 by Center for Disease Control and Prevention, estimated 12901 incidents 
of MRSA at hospitals in the United States (Center for Disease Control and Prevention, 2012). A report 
formed by the World Health Organization (WHO) in 2014 regarding antimicrobial resistance shows 
among others a global examination of MRSA. WHO deduce that in many countries, patients infected 
with S. aureus may instead be treated with second-lined antibacterials, which are more expensive 
and can have side-effects (World Health Organization, 2014). A recent study by Okumura et al. 
(2012) shows that there might be a future treatment towards MRSA. Their results indicated that the 
pharmacological compound AKB-4924 can enhance the gene expression of hypoxia inducible factor-
1 α (HIF-1α) in keratinocytes and phagocytes, which increase their antibacterial activity (Okumura 
et al., 2012). Thus, in this project the possibility of an alternative treatment against MRSA will be 
examined. With emphasis on the innate immune system, it will be examined how the immune 
system can be boosted by stimulating immune cells like neutrophils and macrophages. Hence, a 
minor experiment with macrophages treated with lipopolysaccharides (LPS) and infected with S. 
aureus has been performed regarding this project. The treatment with LPS was done to show if the 
killing ability of macrophages could be increased, and hereby examine if LPS potentially can boost 
the immune system during an infection with S. aureus.  In addition to the experiment, theory 
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concerning the immune system in a healthy patient, and S. aureus in relation to the immune 
mechanisms and its resistance towards methicillin will be included. With this knowledge, it will be 
described how MRSA on a cellular level can affect a healthy patient, and thus, it will be discussed if 
the immune cells can be boosted. Further, it will be discussed what is central when S. aureus attacks 
the immune system, and hereby consider which mechanisms of S. aureus that with benefit could be 
inhibited. Hence, the problem of interest of this project is as follows: 
 
How does S. aureus interfere the immune response of healthy patients, and is it possible to boost 
this response under infection of MRSA without any severe side-effects? 
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Theory 
The immune system defense against bacteria 
This chapter describes the immune response during a bacterial attack in a healthy patient. The focus 
of this chapter will be the innate immune system, including the functions of the immune cells, 
neutrophils and macrophages, and the complement proteins, which are affected by the S. aureus 
counterattack. The adaptive immune system will also be described. This background knowledge of 
the immune system will be used to consider how the S. aureus counterattack affects these immune 
responses. 
The innate immune response 
The innate immune response is the first defense against infectious diseases and does not recognize 
specific pathogens identities, but instead it recognizes the pathogens’ general molecular properties 
(Aderem & Ulevitch, 2000; Widmaier et al., 2014).  
Recognition of foreign molecules on the bacterial surface 
Once the bacteria have successfully invaded the tissue, the innate immune response recognizes 
general molecules on the pathogens’ surface. These molecules are called pathogen-associated 
molecular patterns (PAMPs), including lipids like LPS, carbohydrates and bacterial nucleic acids 
(Aderem & Ulevitch, 2000; Widmaier et al., 2014; Akira et al., 2006). The PAMPs are recognized by 
the phagocytes’ protein pattern-recognition receptors (PPRs). In the innate immune response a 
family of PPRs are the transmembrane glycoproteins Toll-like receptors (TLRs) (Aderem & Ulevitch, 
2000; Widmaier et al., 2014; Akira et al., 2006). The TLR4 recognizes LPS on gram-negative bacteria, 
whereas TLR2 together with TLR1 and TLR6 recognizes PAMPs of gram-positive and gram-negative 
bacteria (Akira et al., 2006; Spaan et al., 2013). The ligand binding of TLR to the PAMP triggers the 
activation of signaling cascades that further leads to the secretion of inflammatory mediators, like 
the interleukin-1 (IL-1), interleukin-12 (IL-12), and tumor necrosis factor-α (TNF-α) (Widmaier et al., 
2014), which functions will be described in the chapter Innate immune boost against MRSA. 
The inflammatory response 
The bacteria invading the tissue initiates the inflammatory response, which is the local response to 
the infection site. The main functions of the inflammatory response are destroying or in some cases 
inactivating the invading bacteria. The phagocytes, neutrophils and macrophages mediate the 
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innate immune response and coordinate additional host responses by synthesizing inflammatory 
mediators and cytokines (Aderem & Ulevitch, 2000; Widmaier et al., 2014). The inflammatory 
response can be divided into chemotaxis and killing of the bacteria by phagocytes or the 
complement systems. 
Chemotaxis 
When the bacteria have successfully invaded the tissue, neutrophils migrate from the blood 
capillaries towards the infected area by the multistage process chemotaxis. This is done in order to 
defend the host against acute bacterial infection (Widmaier et al., 2014; Spaan et al., 2013). 
Margination is the first step in chemotaxis where the activated endothelial cells of the capillaries 
expresses the adhesion molecules P-selectin and E-selectin that bind loosely with the glycoprotein 
P-selectin glycoprotein ligand-1 (PSGL-1) on the neutrophil’s surface. This and the blood flow cause 
the phagocytes to roll along the capillaries wall (Spaan et al., 2013). This is followed by the next 
stage called diapedesis. Here the neutrophil’s selectin activates and cluster β2 integrins by 
interacting with chemoattractants, cytokines or bacterial products. This results in firm adhesion and 
complete stop of the neutrophil on the endothelial cells, where a number of complementary 
adhesion molecules present on the surface of both endothelial cells and neutrophils interacts. These 
receptors and ligands on both cells result in transmigration through the endothelial junction or 
transcellular through the cell and into the inflamed interstitial fluid (Spaan et al., 2013). 
When the neutrophils arrive to the interstitial fluid, they migrate toward the infected and damaged 
tissue by sensing chemotactic factor gradients. These chemoattractants are secreted by activated 
host cells or released by activated complement proteins and activate the phagocytes by binding to 
the membrane G-protein-coupled receptor (GPCR). In the GPCR family, a specific type of receptors 
are the formyl peptide receptor (FPR), which interacts with bacterial proteins that contains 
formylated methionine. These proteins secretes N-formylated proteins and peptides, which induce 
and potentiate chemotaxis, phagocytosis and the generation of oxidative burst in neutrophils and 
monocytes (Spaan et al., 2013). In oxidative burst reactive oxygen species (ROS) are formed, which 
is essential in the defense against bacteria (Chen & Junger, 2012).  The migration of neutrophils is 
later followed by the migration of monocytes that when arrived to the infected area differentiate 
into macrophages (Widmaier et al., 2014). 
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The killing of bacteria by phagocytes 
After the neutrophils have arrived at the infected area, they begin the phagocytosis, the process of 
destroying intracellular pathogens. This process is initiated by the contact between PAMPs and TLRs. 
However, when the body is under a bacterial attack the phagocytosis often needs to be enhanced 
by opsonin, a chemical factor produced by the host cells. Opsonin gets attached to the bacteria and 
binds tightly to the neutrophils and macrophages, which starts the phagocytosis (Widmaier et al., 
2014). The surface contact between bacteria and neutrophils result in endocytosis, the formation 
of a phagosome. The phagosome makes contact with one of the phagocyte lysosomes, and the two 
vesicles fuse together creating a phagolysosome, where the hydrolytic enzymes break down the 
bacteria. Furthermore, the phagolysosome membrane produces oxygen derivatives, such as nitric 
oxide (NO) and hydrogen peroxide that are very effective in destroying the pathogens 
macromolecules. These products are released inside the phagocyte or out of the phagocyte. 
Furthermore, the leukocytes release antimicrobial substances, for example NO, into the 
extracellular fluid, which destroy the bacteria before phagocytosis (Widmaier et al., 2014). 
The killing of bacteria by the complement system 
The complement system consist of at least 30 different plasma proteins that assists in the killing of 
any pathogens both intra- and extracellular, by using three independent pathways: the alternative 
pathway, the classical pathway and the lectin pathway (Spaan et al., 2013). The alternative pathway 
will be described in this section, while the classical pathway will be described in the section about 
adaptive immune response and the lectin pathway will not be further described. Some of the 
complement proteins are always circulating inactivated in the blood. Infection or damaged tissue 
activates one complement protein that initiates a cascade (Widmaier et al., 2014). The complement 
protein C3 initiates a series of events and is therefore a central protein in the complement system. 
The enzyme complex C3 convertase cleaves the complement protein C3 into C3a and C3b. The C3b 
moves to the bacterial surface, where it functions as an opsonin. Phagocytes have a C3b receptor, 
which recognizes and binds to the bacteria for phagocytosis (Spaan et al., 2013). If there is a high 
concentration of C3b, the substrate specificity of the C3 convertase is shifted to the complement 
protein C5, forming the C5 convertase, which cleaves C5. The cleaving of C5 results in C5a, a potent 
chemoattractant for neutrophils, and C5b, which initiates the formation of a multiunit protein, the 
membrane attack complex (MAC) (Spaan et al., 2013; Willey et al., 2011). MAC lyses the bacteria by 
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making porelike channels in the bacterial membrane, which results in free movement of water, ions 
and small molecules across the bacterial membrane. This lysis of the bacteria destroys the 
intracellular environment and kills the bacteria (Widmaier et al., 2014). 
The Adaptive immune response 
The adaptive immune response is specific and can distinguish between the different pathogens 
unlike the innate immune response. The most essential cells in this response are the lymphocytes, 
including T cells and B cells, which must recognize the pathogen before attacking it. The molecules 
that induces any adaptive immune response against itself, or the cell bearing this molecule 
regardless of functions and locations, are called antigens. They are either specific proteins or large 
polysaccharides on foreign cells and toxins (Widmaier et al., 2014). Some T cells and B cells 
differentiate into memory cells that permit the immune defense to respond faster next time this 
particularly pathogen attacks (Widmaier et al., 2014). 
Activation of B cells leads to phagocytosis of the bacteria 
Helper T cells migrate towards the lymph nodes where they interact with antigen presenting B cells. 
This direct contact leads to the release of cytokines by the helper T cells that thereby activates the 
B cells (Widmaier et al., 2014). Once the B cells are activated, they differentiate into plasma cells 
that secrete immunoglobulin (Ig) receptors called antibodies that recognize the specific bacterial 
antigen. The Ig receptors are divided into five different classes: IgA, IgB, IgE, IgG and IgM. IgG and 
IgM provide the specific immunity against bacteria and viruses, and they will therefore be in focus 
in this project.  The plasma cells produce thousands of IgG and IgM antibodies per second that are 
secreted into the circulation system. They circulate into the infected area, where they get past the 
endothelial cells, similar to those in the inflammatory response (Widmaier et al., 2014). In the 
infected area, the antibodies enhance the phagocytosis by directly acting as opsonins, similar to the 
complement C3b. In this process, the antibodies bind to the bacterial antigen and the fragment 
crystallizable (Fc) portion of the antibodies binds to the phagocytes’ (neutrophils or macrophages) 
membrane or complement proteins. This binding triggers the phagocytosis (Fig.  1. A) (Widmaier et 
al., 2014). The antibodies released by the plasma cells also activates the classical complement 
pathway by binding with bacterial antigen. First, the complement protein C1q binds to the 
complement-binding site of the IgG or IgM Fc portion that are bound to the bacterial antigen. This 
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binding activates C1q, which then activates C1r and C1s leading to the cleavage of C4. This is 
followed by the formation of C3 convertases, which in the end leads to killing of the bacteria by MAC 
(Fig. 1. B) (Danobeitia et al., 2014; Widmaier et al., 2014). Furthermore, neutrophils and 
macrophages get their phagocytosis enhanced by the C3b molecule that acts like an opsonin. Hence, 
antibodies enhance phagocytosis via activation of complement C3b (Widmaier et al., 2014). In 
addition, the antibodies directly neutralize the toxins secreted into the extracellular fluid by the 
bacteria. The toxins act as antigens that can bind with the antibodies. This creates clump-like chains 
of antibody-antigen complexes, which are phagocytized (Widmaier et al., 2014). 
 
Fig. 1. A: The antibodies bind to the bacterial antigen and directly link the bacteria with the phagocytes, 
leading to enhanced phagocytosis. B) The activation of the classical pathway. The antibody binds the bacterial 
antigens and this leads to the C1 binding to the Fc portion of the antibody. This results in the formation of 
MAC (Edited from Widmaier et al., 2014). 
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S. aureus in proportion to methicillin resistance and the immune system 
In this chapter, the bacteria S. aureus are in focus. The bacterium's function as a gram-positive 
bacteria will be described followed by a description of how the S. aureus developed resistance 
towards penicillin, with focus on its methicillin resistance. The mechanisms by which S. aureus 
attacks and avoids the immune system are outlined, including a description of how some of the 
proteins, that S. aureus secretes, affect complement proteins, neutrophils and the TLR signaling. 
These are important factors of the immune response towards invading bacteria.    
S. aureus’s function as a gram-positive bacteria 
The pathogen S. aureus is known to cause skin infections (Deurenberg & Stobberingh, 2008; Navarre 
& Schneewind, 1999). S. aureus exists naturally in colonies on a large percentage of the human body, 
but the amounts of colonies depend on your health. People with diseases or patients who 
undergoes surgical procedures contains a larger amount of colonies and are thereby at higher risk 
of an infection by S. aureus. The infections that S. aureus causes are skin and tissue damages, 
infections in bones and in the respiratory system, and endocarditis (Lowy, 1998). S. aureus produces 
cytotoxines that cause inflammatory changes in the host cells and furthermore it produces enzymes, 
which destroy the host’s tissue (Lowy, 1998). The gram-positive bacterium is characterized by its 
cell wall, which consists of a thick layer of peptidoglycan. The cell wall of S. aureus has the quality 
to grow and divide, while the cell wall is kept intact (Navarre & Schneewind, 1999). The cell wall of 
gram-positive bacteria synthesizes a peptidoglycan polymer chain. This chain will make a cross-
linkage with help from its penicillin-binding-protein (PBP), which is a transpeptidase enzyme. This 
cross-linking makes the cell wall of gram-positive bacteria rigid, which can lead to cell lysis (Lee et 
al., 2015). 
How S. aureus developed resistance  
Penicillin is an antibiotic that prevents infections caused by S. aureus. It contains β-lactam, which 
affects the specific blaZ gene of the penicillin resistant S. aureus to synthesize the enzyme β-
lactamase. This enzyme inhibits the β-lactam antibiotic (Lee et al., 2015; Lowy, 2003; Zhang et al., 
2001). S. aureus have developed resistance towards methicillin, which is a type of penicillin 
antibiotic. Responsible for this resistance is the mecA gene found in MRSA. The mecA gene expresses 
the penicillin-binding-protein 2a (PBP2a), which function is to help making a cross-linkage of the 
peptidoglycan polymer chain (Deurenberg & Stobberingh, 2008; Lowy, 2003). PBP2a is similar to 
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other PBPs but differ in the way, that their active site blocks the binding of all β-lactams (Lowy, 
2003). The transcription of mecA is regulated by mecI, which functions as a repressor. Furthermore, 
the mecR1 is a methicillin resistant protein that function as a signal-transducer, which sense β-
lactam and regulate mecA (Deurenberg & Stobberingh, 2008). 
The mecA is a complex gene placed at staphylococcal cassette chromosome mec (SCCmec), which 
is found close to the replication origin. SCCmec is composed of two types of gene complexes, where 
mecA is responsible for S. aureus’ resistance towards β-lactam. The second complex, ccr, controls 
the movement of SCCmec. There are several types of SCCmec (Fig. 2). They differ in the combination 
of mecA and which ccr complex that are present. The SCCmec types are SCCmec I, IV ,V ,VI and VII, 
which all contains the antibiotic resistance gene mecA, whereas II and III both contain different 
genes, that also cause S. aureus to be resistant to several classes of antibiotics (Deurenberg & 
Stobberingh, 2008; Ito et al., 2003).  
 
 
Fig. 2: The different types of SCCmec genes from I to VII in the methicillin resistant S. aureus, shown in a 
simplified version. They all consist of the gene responsible for resistance, mecA, and different ccr complexes 
responsible for the movement of SCCmec. Furthermore, they all contain mecRI or mecI that both regulates 
mecA (Inspired by Deurenberg & Stobberingh, 2008; Ito et al., 2003). 
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How S. aureus attacks and avoid the immune system 
The immune system is affected by S. aureus. The bacterium secretes different proteins that impair 
specific parts of the immune mechanism. Some of these proteins are Staphylokinase (SAK), the 
chemotaxis inhibitory protein of Staphylococcus aureus (CHIPS), staphylococcal superantigen-like 
proteins (SSLs) and the staphylococcal complement inhibitor (SCIN). In S. aureus, the genes encoding 
SAK, CHIPS and SCIN are clustered on the pathogenicity island SaP15, and additionally all proteins 
on this specific pathogenicity island are human specific (Rooijakkers et al., 2005). The staphylococcal 
pathogenicity island 2, which is found in all the S. aureus strains, encodes the SSL genes (Bestebroer 
et al., 2007). 
The mechanisms of SCIN and SAK immune interference 
The protein SCIN is present in 90 % of S. aureus strains and blocks the classical and the alternative 
pathway.  At the surface of a bacterium, SCIN stabilizes the C3 convertases C3bBb and C4b2a, which 
prevents further production of convertases. Additionally, the activity of the C3bBb and C4b2a is 
inhibited when SCIN binds to them (Rooijakkers et al., 2005; Chavakis et al., 2007). SAK can bind the 
peptides α-defensins, leading to an inhibition of the bactericidal effect that the α-defensins have on 
S. aureus. Defensins are antibacterial proteins that attend in the destruction of bacteria after 
neutrophils have engulfed them by phagocytosis. The destruction takes place in endocytotic 
vacuoles (Rooijakkers et al., 2005; Widmaier et al., 2014). SAK can also activate plasminogen, a 
zymogen that is bound to the surface of S. aureus, where many plasminogen-binding receptors are 
expressed. When plasminogen is activated, it is converted into plasmin, which surface-bound can 
cleave IgG and C3b. The Fc fragment of IgG is removed when IgG is cleaved, and this fragment 
contains the glycosylation site that enables C1 to recognize IgG. The cleavage of C3b decreases the 
number of C3b, which leads to a reduction in the number of C3 and C5 convertases. The 
phagocytosis by the human neutrophils are inhibited by the cleavage of IgG and C3b (Rooijakkers et 
al., 2005; Chavakis et al., 2007). 
CHIPS and SSL7 inhibit pathways of C5  
On neutrophils, there are the receptors C5aR and FPR. The function of these receptors can be 
impaired by the protein CHIPS that is found in 60 % of S. aureus strains. CHIPS binds specifically to 
C5aR and FPR, which means that the ligands of the receptors cannot bind and the inducement of 
signal transduction will be blocked (Fig. 3) (Rooijakkers et al., 2005; Postma et al., 2004). The ligand 
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of C5aR is the anaphylotoxin C5a, which is generated from the complement glycoprotein C5 that is 
cleaved by C5 convertases into C5a and C5b, respectively. This process can be inhibited by SSL7, 
which is one out of 11 SSLs that are secreted by S. aureus. SSL7 binds with C5 preventing it from 
being cleaved by the C5 convertases (Bestebroer et al., 2010; Langley et al., 2005; Chavakis et al., 
2007). SSL7 also binds the antibody IgA, and thereby prevents IgA from binding to its receptor FcaRI 
(Bestebroer et al., 2010; Langley et al., 2005). It is suggested by Bestebroer et al. (2010) that when 
SSL7 is bound to IgA, it may increase SSL7’s inhibitory activity on C5. 
 
 
Fig. 3: A leukocyte with the two receptors, C5aR and FPR. CHIPS blocks the receptors, so their ligands C5a 
and formylated peptides (fMLP) cannot bind (Edited from Chavakis et al., 2007). 
The influence of SSL3 on TLR signaling 
S. aureus also secretes SSL3 and SSL4, which target TLR2. The extracellular domain of TLR2 is 
specifically bound by SSL3 and SSL4, but SSL3 has a much higher inhibitory activity than SSL4. SSL3 
only binds to TLR2, meaning no other TLRs are bound by SSL3 (Bardoel et al., 2012). Bardoel et al. 
(2012) suggest that the inhibition of TLR2 caused by SSL3 may be due to the ligand binding of TLR2 
is blocked by SSL3, or the dimerization of the heterodimers TLR1/TLR2 or TLR2/TLR6 is affected by 
SSL3. The dimerization is important for receptor signaling (Bardoel et al., 2012). According to 
Bardoel et al. (2012) human neutrophils and monocytes of the innate immune system are 
specifically bound by SSL3, but SSL3 is not able to bind to lymphocytes of the adaptive immune 
system. SSL3 may also affect the innate immune cells, dendritic cells and macrophages, which are 
able to express TLR2 (Bardoel et al., 2012). 
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Interference of PSGL-1 and P-selectin binding by SSL5 
SSL5 can inhibit the rolling of the neutrophils on the endothelium, that occurs when there is an 
infection, by interfering the mechanism between P-selectin glycoprotein ligand- 1 (PSGL-1) and P- 
selectin. PSGL-1 is found on i.a. neutrophils, and according to Bestebroer et al. (2007), PSGL-1 is 
bound by SSL5, which prevents binding of PSGL-1 to P-selectin that is located on activated 
endothelial cells (Fig. 4). The affinities of SSL5 and P-selectin for PSGL-1 are equal (Bestebroer et al., 
2007; Chavakis et al., 2007). When P-selectin cannot bind to PSGL-1, the rolling adhesion of 
neutrophils towards the activated endothelial cells is inhibited. This may cause that the neutrophil 
extravasation from the blood vessels to the infected area is prevented (Bestebroer et al., 2007). The 
experiment of Bestebroer et al. (2007) indicated that neutrophils, monocytes and natural killer cells 
were bound strongly by SSL5, and it was almost unable to bind to B and T lymphocytes.     
 
Fig. 4: SSL-5 binds to PSGL-1 and blocks the binding between the leukocytes’ PSGL-1 and the endothelial cells’ 
P-selectin (Edited from Chavakis et al., 2007).  
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Innate immune boost against MRSA 
MRSA infections cannot be treated with antibiotics, and therefore alternative treatments against 
MRSA are examined today. Thus, this section will describe how HIF-1 and LPS can be used to boost 
the innate immune system during an infection with MRSA. 
 
HIF-1α boosted immunization against MRSA 
The transcription factor HIF-1 is a heterodimer that consist of the two subunits HIF-1α and HIF-1β. 
HIF-1 is upregulated under conditions with low oxygen and regulates gene expression of certain 
genes in order to adapt cells to the low oxygen stress (Okumura et al., 2012; Nelson & Cox, 2013). 
It has been shown that HIF-1 is also upregulated when cells are infected with bacteria independently 
on the level of oxygen (Peyssonnaux et al., 2005). HIF-1α is expressed in keratinocytes and 
phagocytes, like neutrophils, macrophages and monocytes, where it regulates gene transcription of 
certain genes. Thus, HIF-1α is important in the innate immune response (Peyssonnaux et al., 2005; 
Peyssonnaux et al., 2008; Okumura et al., 2012). A study by Okumura et al. (2012) shows that a new 
pharmacological compound called AKB-4924 is a HIF-1α stabilizing agent. AKB-4924contains the iron 
binding group α-hydroxycarbonyl, which is thought to bind to the iron binding site of the enzyme 
prolyl hydroxylase 2 (PHD2) (Fig. 5). When AKB-4924 binds to PHD2 it inhibits the activity of the 
enzyme, which would otherwise target HIF-1α for degradation by a specific pathway called the 
ubiquitin-proteosome pathway, which will not be further described (Okumura et al., 2012). 
Treatment with AKB-4924 increases the antibacterial activity of keratinocytes and phagocytes 
against bacteria like MRSA by enhancing the amount of HIF-1α in keratinocytes and phagocytes (Fig. 
6) (Okumura et al., 2012).  
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Fig. 5: The structure of AKB-4924. Z denotes phenyl substituted with one to five fluorines or chlorines and R4 
denotes either a linear alkyl or a branched alkyl group. AKB-4924 contain an iron binding group, α-
hydroxycarbonyl, which is marked in the figure (Okumura et al., 2012). 
The production of NO is increased by HIF-1α in macrophages. NO is important in bacterial killing and 
in stabilization of HIF-1α. This stabilization of HIF-1α in macrophages is according to Peyssonnaux et 
al. (2005) central for an increased expression of TNF-α, which is a cytokine important for the 
inflammatory response against infection with bacteria (Peyssonnaux et al., 2005). The function of 
TNF-α in the immune system is described in more details, under the section about LPS. In 
keratinocytes HIF-1α upregulates expression of human cathelicidin, LL-37 (Peyssonnaux et al., 
2008). Cathelicidins are peptides that form pores in the plasma membrane of bacteria and thereby 
damage the membrane (Willey et al., 2011). Okumura et al. (2012) have shown this upregulation of 
cathelicidin, where transcription of LL-37 is upregulated in monocytes treated with AKB-4924. In the 
same study and a study by Leire et al. (2013) it was measured that expression of interleukin-8 (IL-8) 
is upregulated in monocytes and keratinocytes, when treated with AKB-4924. IL-8 is a pro-
inflammatory cytokine, which functions as a chemoattractant for neutrophils, and this means that 
IL-8 is important for migration of neutrophils toward the infected site (Okumura et al., 2012; Leire 
et al., 2013). Expression of vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) is 
upregulated in keratinocytes, when treated with AKB-4924 (Leire et al., 2013). IL-6 enhances 
bacterial killing by neutrophils while VEGF is important for formation of new blood vessels (Hruz et 
al., 2009; Nelson & Cox, 2013). HIF-1α upregulates transcription of IL-1β in macrophages under 
hypoxic conditions (Fang et al., 2009). The function of IL-1 in the immune system is described in the 
section about LPS. Fig. 6 gives an overview of the impact by AKB-4924 on the expression of genes 
controlled by HIF-1α. 
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Fig. 6: AKB-4924 inhibits the enzyme PHD2 and therefore the amount of HIF-1α increases. HIF-1α increases 
the antibacterial activity of keratinocytes and phagocytes by regulating the expression of specific genes in 
these. HIF-1α increases expression of LL-37, VEGF, TNF-α, NO and the interleukins IL-1β, IL-6 and IL-8. All of 
these agents are important for the inflammatory response, caused by bacteria like MRSA (Illustrated by Rikke 
Svendsen, 2015). 
LPS boosted immunization against MRSA 
LPS is an endotoxin found on the outer layer of gram-negative bacteria. It consists of two 
polysaccharide components and a lipid component. The O-antigenic chain and the core 
oligosaccharide are the two polysaccharide components, where the last mentioned combines the 
O-antigenic chain with the lipid component of LPS, lipid A, which is known to be the toxic part of 
LPS, that can cause septic shock (Fig. 7) (Beutler & Rietschel, 2003; Zähringer et al., 1999). 
 
Fig. 7: The chemical structure of LPS contains the O-specific chain and the core region, which is bound to the 
toxic part of LPS, Lipid A (Beutler & Rietschel, 2003). 
When LPS enters the host, it affects the immunity of the host by binding to and activating 
macrophages. First LPS is recognized and binds to the LPS-binding protein (LBP), which is produced 
by the liver. This binding promotes the binding of LPS monomers to the glycosylphosphatidylinositol 
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protein, CD14, found on the cell surface of macrophages (DeFranco et al., 1999). CD14 functions as 
an LPS-receptor, but is also known to promote the binding of macrophages with activated T cells 
(Ulevitch & Tobias, 1995). Besides LBP, LPS is also recognized by the toll-like receptor 4 (TLR4), which 
is found on the surface of macrophages (DeFranco et al., 1999). When LPS binds to TLR4 it initiates 
a TLR signaling pathway, which contains different kinases. This cascade of reactions will not be 
further described. The result of the TLR signaling pathway is an activation of the transcription factor, 
nuclear factor kappaB (NF-kB) (Aderem & Ulevitch, 2000). NF-kB induces expression of the cytokines 
IL-1, IL-6 and IL-8 (Fig. 8) (Medzhitov et al., 1997). These recognitions of LPS by CD14 and TLR4, also 
leads to secretion of the pro-inflammatory compounds, such as TNF-α and IL-12. Furthermore, it 
also results in generation of the toxic NO (Fig. 8) (DeFranco et al., 1999). IL-1, IL-6 and TNF-α are 
important for both the production and release of leukocytes. These cytokines are also important for 
induction of fever, which is one of the responses to infection and inflammation. IL-1, IL-6 and IL-8 
are also important in regulation of growth and differentiation of lymphocytes. The activation of 
helper T cells in the adaptive immune system is stimulated by IL-1, IL-6 and TNF-α (Widmaier et al., 
2014; Willey et al., 2011). The interleukin IL-8 stimulates cell migration of leukocytes and attracts 
phagocytic cells. The last upregulated agent is interleukin IL-12, which is important in regulation of 
differentiation and growth of T cells (Willey et al., 2011).   
The LPS-induced macrophages respond to LPS by an increase of tyrosin phosphorylation of several 
proteins. The binding of LPS to CD14 permits the tyrosin phosphorylation, but the phosphorylation 
also depends on the concentration of LPS. A low concentration of LPS will result in CD14 blocking 
the tyrosin phosphorylation of proteins. Conversely, a high concentration results in the 
phosphorylation (Ulevitch & Tobias, 1995). One group of proteins, which are phosphorylated, are 
the mitrogen-activated protein kinase (MAPK), which sends extracellular signals into the cells 
(Ulevitch & Tobias, 1995; Cano & Mehadevan, 1995). MAPK consists of the three subfamilies, 
extracellular-signal-regulated kinase 1 and 2 (Erk-1 and Erk-2), c-Jun N-terminal protein kinase 1 and 
2 (JNK) and p38, that all are activated by the tyrosin phosphorylation because of the response to 
LPS (Defranco et al., 1999; Cano & Mahadevan, 1995). Activation of the subfamilies ERK and JNK 
results in phosphorylation of transcription factors. In general LPS-induced macrophages result in 
activation of the MAPK, which leads to further activations of several genes that are part of the host 
immune system (Fig. 8) (Hambleton et al., 1996). 
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Fig. 8: LPS can bind to the CD14 receptor through LBP or it can bind to the TLR4 receptor. When bound to 
CD14 it results in a phosphorylation and thereby an activation of MAPK. When LPS binds to TLR4 it initiates 
the TLR signaling pathway, which results in activation of NF-kB. The activation of MAPK and NF-kB leads to 
an increased expression of IL-1, IL-6, IL-8, IL-12, TNF-α and NO, which are all important in the inflammatory 
response (Illustrated by Rikke Svendsen, 2015).    
 
  
24/62 
 
Hypothesis 
LPS binds to macrophages and stimulates them to secrete different cytokines in order to kill S. 
aureus. Thus, it is expected that LPS stimulates the macrophages to kill S. aureus and will therefore 
have an effect on the amount of S. aureus released from the macrophages, when exposed to Triton-
X. Since LPS stimulates the macrophages, it is expected that the amount of S. aureus is lower for the 
macrophages that are treated with LPS than the macrophages that are not treated with LPS.  
Furthermore, it is expected that the amount of this bacteria will decrease if the time that the 
macrophages are exposed to LPS is increased, because the macrophages are stimulated for a longer 
time. It is also expected that the longer time the macrophages have been exposed to S. aureus the 
fewer bacteria are observed on the LB-plates, because then the macrophages have more time to 
phagocytize S. aureus. 
Method 
This chapter contains the description of the methods used to determine if LPS boost the bacterial 
killing by macrophages during an infection with S. aureus. The experiment was divided into three 
phases; the preparation of macrophage cells, preparation of S. aureus and the infection of 
macrophages with S. aureus. The experiment was conducted two times. 
Preparation of the macrophage cells 
The macrophage cells from the cell line J774A.1, were cultivated with the medium Roswell Park 
Memorial Institute (RPMI), 10 % fetal bovine serum (FBS), 25mM HEPES buffer and the antibiotic 
gentamicin. Afterwards the cells were subcultivated twice and kept warm in an incubator at 37 oC. 
There were made LB-plates with hot medium and eppendorf tubes, each containing 900 µl sterile 
saline.  
The cells were prepared for harvest, by first removing the medium and then washed with 11 ml 
warm Dulbecco's Phosphate Buffered Saline (DPBS). They were harvested by adding 10 ml warm (37 
oC) medium (RPMI and FBS) and scraped loose with a “window- scraper”. The cell-suspension was 
centrifuged with 1500 rpm for 9 min. at room temperature (23 oC). Afterwards the supernatant was 
removed. Before counting the cells, they were resuspended in 1 ml warm medium and diluted 10 
times in an eppendorf tube. 2 x 10 µl were added to the counting chamber and two areas were 
25/62 
 
counted. In the first experiment 103 cells and 110 cells were counted, resulting in an average of 107 
cells. The average number of cells was multiplied by the dilution factor 10. To get the amount in 
cells/ml it was hereafter multiplied by 10000, because the volume of the counting table was 0.1 µl. 
The amount of cells/ml in the harvest tube was estimated to be 107x10x10000 = 1.07x107 cells/ml 
and had to be adjusted to 6x105 cells/ml. The dilution factor was estimated to be 1.07x107/6x105 = 
17.83 (Table 1). Based on this calculation 1 ml cells and 16.83 ml medium were mixed and 400 µl 
were distributed in 8 wells on three 24-well-plates for the harvest times 0.5, 2 and 24 hours. Two 
wells on each plate were negative controls without bacteria, two wells were not treated with 
LPS and two wells were treated with LPS for 2 hours and two for 24 hours before infection. 40 µl 
LPS were added to two wells on each plate marked with LPS24 before the cells were incubated over 
the night. 
Table 1: The average macrophages counted in the counting chambers and the dilution factor for adjusting to 
6x105 cells/ml, in both the first and the second experiment. 
 First experiment Second experiment 
The average number of cells 107 91.5 
Dilution factor 17.8 15.25 
 
The next day the media was removed and the cells were washed gently with 1 ml warm DPBS. Then 
0.5 ml warm fresh RPMI and FBS media were added to all the wells and hereafter 40 µl LPS were 
added to the wells that had to be treated with LPS for 24 hours and 2 hours. Before infection with 
the S. aureus culture, the plates were incubated at 37 oC, 5% CO2 for 2 hours.  
Preparation of S. aureus 
S. aureus was inoculated in 5 ml LB medium and incubated at 37 oC with shaking over night. Then 
the S. aureus culture was prepared by harvesting 2 ml culture into two 14 ml centrifuge tubes. 
Hereafter the tubes were centrifuged at 8000 rpm for 8 min. and then the supernatant was 
removed. Subsequently, the cells were resuspended in 5 ml saline and then the OD600 was measured 
to 1.032, in the second experiment. The solution was diluted with saline to a concentration of 5x108 
cells/ml, which corresponds to OD600 = 0.5. The calculation of the dilution factor was 1.032/0.5 = 
2.064. Therefore, 2 ml of the bacteria were added to 2.128 ml saline to obtain a total volume of 
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4.128 ml. The cells were further diluted to a concentration of 5x106, which was used as the infection 
solution also called inoculum. This dilution was made with two 10-fold dilutions, by first transferring 
1 ml of the 5x108 dilution to 9 ml saline and hereafter transferring 1 ml from this 5x107  dilution to 9 
ml saline.  
The colony-forming unit (CFU) was determined by first making six 10-fold dilutions to 10-6. This was 
done by first making a 10-1 dilution, by mixing 100 µl from inoculum with 900 µl saline. Hereafter 
100 µl of the 10-1 dilution was mixed with 900 µl saline. In this way a 10-2 dilution was made and this 
step was repeated four times in order to get a 10-6 dilution of inoculum. In order to determine the 
CFU of the inoculum 4x10 µl of the 10-3, 10-4, 10-5 and 10-6 dilutions were spotted on one LB-plate. 
The plate was incubated at 37 oC until next day.  
The infection of macrophages with S. aureus 
The infection was started by adding 100 µl inoculum with a concentration of 5x106 cells/ml to each 
well with macrophages, except for the two wells for negative controls. Then the three plates were 
centrifuged at 300 rpm for 3 min., in order to spin the bacteria down to the cells. Hereafter the 
plates were incubated for 25 min. at 37 oC and 5 % CO2. After incubation, the media was removed 
from all the plates and then the cells were washed twice with 1 ml warm DPBS. 0.5 ml fresh media 
with 25 µg/ml gentamicin was added to all wells in all plates and hereafter they were incubated at 
37 oC and 5 % CO2. At the time, the plates were placed in the incubator the time 0 was noted. 
Gentamicin was added to kill the bacteria that were not phagocytized by the macrophages. After 30 
min. one plate was harvested by removing the media and hereafter washed twice with 1 ml warm 
DPBS. Then 1 ml 0.1 % Triton-X was added to two wells, which was hereafter scraped with a pipette-
tip. Triton-X lyses the macrophages, resulting in the bacteria being released into the solution. The 
reason why we only did this with two wells at a time was to reduce the time that the bacteria are 
exposed to Triton-X. Three 10-fold dilutions were made by transferring 100 µl of the cells to 900 µl 
saline, in this way 10-1, 10-2 and 10-3 dilutions were made in the first experiment. In the second 
experiment 100, 10-1 and 10-2 dilutions were made. In order to determine the CFU, 4x10 µl of the 
three dilutions were spotted on LB-plates, which were incubated at 37 oC until next day (Fig. 9). This 
was repeated for all the wells, except for the negative controls, which was spotted directly on LB-
plates without dilution after treatment with Triton-X. This procedure was repeated with the samples 
infected for 2 and 24 hours. At last, all the CFU results were counted.   
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Fig. 9: A LB-plate spotted with bacteria from macrophages without any added LPS. At the harvest time 0.5 
hour and comes from well two. The dilution factor is indicated on the right side where 0=100, -1=10-1 and  
-2=10-2. 
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Results 
This chapter contains the results from the experiment of this project. First, the total average of 
CFU/ml of S. aureus is presented in a table and in the corresponding bar chart with 95 % confidence 
intervals (95 % CI). The level of significance was chosen to be p = 0.05 in order to make a t-test. This 
means that if the p-value is larger than 0.05, there is no significant difference between the two 
measured values, and if it is lower than 0.05, then there is a significant difference. At last, results of 
the t-tests are presented. 
Total CFU/ml 
The average of S. aureus in CFU/ml was in both experiments found by counting the colonies on the 
LB-plates. Then the total average in CFU/ml of these two experiments was calculated (Table 2; Fig. 
10). A colony represents a S. aureus that was inside a macrophage and released at the specific 
harvest time due to the lysis caused by Triton-X. The observed amount of S. aureus indicates how 
effective the macrophages killed the bacteria depending on which LPS treatment they were given. 
The LPS treatment can be divided into macrophages that were not treated with LPS (-LPS), those 
treated with LPS for two hours (LPS2) and those treated with LPS for 24 hours (LPS24). Each 
treatment were harvest after 0.5, 2 and 24 hours. The 95 % CI was calculated for each CFU/ml of 
the different LPS treatments and their respective harvest time. This was done in order to determine 
the reliability of the data. 
Table 2: The total average of S. aureus in CFU/ml of that have been infecting macrophages that were not 
treated with LPS (-LPS), those treated with LPS for two hours (LPS2) and those treated with LPS for 24 hours 
(LPS24). Each treatment were harvested after 0.5, 2 and 24 hours. 
Total average 
(CFU/ml) Time (hours) 
-LPS 
(CFU/ml) 
LPS2 
(CFU/ml) 
LPS24 
(CFU/ml) 
  0.5 28188.89 7812.50 14091.67 
  2 31531.25 4432.29 6251.04 
  24 12894.79 4193.75 2564.58 
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In Table 2 and Fig. 10 it can be observed that the highest amounts of S. aureus are the -LPS groups 
with 28188.89 CFU/ml, 31531.25 CFU/ml and 123894.79 CFU/ml at 0.5, 2, and 24 hours, 
respectively. At the harvest times 0.5 and 2 hours, LPS24 has the second highest total averages at 
1409.67 and 6251.04 CFU/ml, respectively, and LPS2 has the lowest at 7812.5 and 4432.29 CFU/ml, 
respectively. At the harvest time 24 hours it can be observed that LPS24 has the lowest total average 
at 2564.58 CFU/ml, and LPS2 have the second highest at 4193.75 CFU/ml. It can also be observed 
that the total averages of LPS2 and LPS24 decrease with increasing harvest time. The total average 
of –LPS is highest at 2 hours followed by 0.5 hour and is lowest at 24 hours. 
 
 
Fig. 10: The total averages of S. aureus released from macrophages, in CFU/ml, in regards to the harvest times 
0.5, 2 and 24 hours. The blue bars represent S. aureus from the untreated (-LPS) macrophages, the orange 
bars represent S. aureus from macrophages exposed to LPS for 2 hours (LPS2) and the grey bars are S. aureus 
from macrophages exposed to LPS for 24 hours (LPS24). The error bars are the 95 % confidence intervals. 
 
The 95 % CIs at the harvest time 0.5 hour are (7288.59; 49089.19), (-6227.31; 21852.31) and (-
13595.83; 41779.17) for the treatments –LPS, LPS2 and LPS24, respectively (Appendix). These 
intervals indicate that the population mean for each treatment lies in the corresponding interval 
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with 95 % certainty. The intervals overlap each other, which indicate that there are no differences 
between the total averages. The same applies to the treatments at the harvest time 24 hours, and 
the treatments LPS2 and LPS24 at the harvest time 2 hours. The 95 % CIs of LPS2 and LPS24 do not 
overlap the interval of –LPS at the harvest time 2 hours. This indicate that there are differences 
between these total averages.  
Statistical analysis 
To compare the mean of each data set with each other and to compare whether the data sets are 
significantly different from each other a t-test was made. This was done in order to observe if LPS 
stimulates the killing of S. aureus by macrophages. In Table 3 it can be observed that there is a 
significant difference between –LPS and LPS2 after the infection with S. aureus for 0.5 and 2 hours, 
but not after 24 hours of infection. The t-tests shows statistically that there are a significant 
difference between –LPS and LPS24 at the harvest times 2 and 24 hours, but not at 0.5 hour. The p-
value at 24 hours is close to the significance level 0.05, and therefore there might not be a significant 
difference between –LPS and LPS at 24 hours. The last comparison between LPS2 and LPS24 shows 
that there is no significant difference between any of the harvest times.   
Table 3: A summary of all the p-values of the treatments –LPS, LPS2 and LPS24 at the harvest times 0.5, 2 and 
24 hours.  
 Harvest time (hours) p-values 
 
LPS2 & -LPS 
0.5 0.02<P<0.025 
2 0.0005<P<0.005 
24 0.05<P<0.1 
LPS24 &-LPS 
0.5 0.10 <P<0.20 
2 0.0005<P<0.005 
24 0.04 <P<0.05 
 
LPS24 & LPS2 
0.5 P>0.20 
2 P>0.20 
24 0.10 <P<0.20 
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Furthermore, a t-test were made for the different harvest times with the three LPS treatments. It 
can be observed from Table 4, that there is no significant difference between the harvest times 0.5 
and 2 hours for –LPS, LPS2 and LPS24, respectively. This is also the case for the comparison of the 
harvest times 0.5 and 24 hours for all three treatments. There is a significant difference between 
the harvest times 2 and 24 hours for –LPS and LPS24, respectively. However, there is no difference 
between the harvest times for LPS2.   
Table 4: A summary of all the p-values of the different harvest times 0.5, 2 and 24 hours of the three 
treatments –LPS, LPS2 and LPS24.   
 LPS treatments p-values 
0.5 hour & 
2 hours 
-LPS P>0.20 
LPS2 P>0.20 
LPS24 P>0.20 
0.5 hour & 
24 hours 
-LPS 0.10 <P<0.20 
LPS2 0.10 <P<0.20 
LPS24 0.10 <P<0.20 
2 hours & 
24 hours 
-LPS 0.01 <P<0.02 
LPS2 P>0.20 
LPS24 0.01 <P<0.02 
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Discussion  
This chapter contains the discussion of which effects a MRSA infection may have on the immune 
response, including the possible consequences of an infection. Furthermore, it is discussed whether 
it is possible to boost the complement system and the TLR signaling without any side-effects. Finally, 
the results of the experiment are discussed in regards to the hypothesis.   
The possible consequences of MRSA infection on the immune response  
When MRSA cannot be treated, it can have different consequences on the immune response. As 
mentioned S. aureus secretes many different proteins that may interfere with the immune 
mechanisms, and some of these proteins are SCIN, SAK, CHIPS, SSL7, SSL3, and SSL5. Most of these 
six proteins directly impair the complement system, except for SSL3 that may inhibit TLR signaling, 
which is discussed later in this chapter.  
SCIN inhibits the activity of C3 convertases, which function is to cleave C3 to C3a and C3b. Thus, an 
inhibition of this enzyme means that the cleavage of C3 might decrease, leading to a lower amount 
of C3a and C3b. At the bacterial surface, C3b functions as an opsonin, which phagocytes will bind 
to. In the absence of C3b, the phagocytosis of the bacteria might be reduced. Further, the activity 
of MAC and C5 convertases is regulated by C3b, and its presence leads to the activation of both. The 
consequences of a lowered amount of C3b may result in no activation of MAC and C5 convertases, 
which will overall have a negative effect on the lysis and phagocytosis of the bacteria, respectively. 
When the C5 convertases are inactive, C5 will not be cleaved to C5a and C5b, and the 
chemoattraction of the neutrophils to the infected site and the activation of MAC will be interfered 
and thus, the phagocytosis and lysis are prevented. SSL7 and CHIPS can also affect these 
mechanisms. SSL7 prevents the cleavage of C5, and CHIPS blocks the binding of C5a to C5aR on 
neutrophils. A study by Bestebroer et al. (2007) suggests that the migration of neutrophils towards 
the infected area are impaired by SSL5 due to the binding of SSL5 to PSGL-1. If the neutrophils do 
not arrive to the infected site, they will not bind to GPCR, including FPR that interacts with bacterial 
proteins containing formylated methionine. Hence, these proteins cannot initiate and increase the 
effect of chemotaxis, phagocytosis and the generation of oxidative burst in neutrophils.          
SAK impair indirectly the step of C5 convertases in the pathway by cleaving C3b, which decrease the 
number of C3 and C5 convertases resulting in a reduced amount of C5a that can bind to C5aR. IgG, 
which is primarily produced under bacterial infection, is also cleaved by SAK, and hereby IgG will not 
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bind to the bacterial antigens. This prevents the neutrophils and macrophages from recognizing the 
bacteria impairing the phagocytosis. Furthermore, IgG activates the classical pathway of the 
complement system by binding to C1, but the cleavage of IgG makes C1 unable to recognize it due 
to the removal of the glycosylation site of IgG. Thus, the formation of C3 convertases is inhibited, 
ultimately interfering the phagocytes and MAC from killing the bacteria (Fig. 11). If the amount of 
IgM is not reduced, then this antibody can initiate the classical pathway, but the activity of the 
classical pathway may be diminished due to the cleaved IgG. The neutralization of the toxins from 
the bacteria may also be inhibited because of missing IgG.  
All these pathways that S. aureus may impair might be prevented by examining how parts of the 
complement system could be boosted.     
  
34/62 
 
 
 
Fig. 11: An overview of how CHIPS, SAK, SCIN, SSL5, and SSL7 affects the immune response and how the 
alternative pathway is initiated. SAK cleaves IgG leading to interference of the initiation of the classical 
pathway. This pathway can instead be initiated by IgM. The initiation of phagocytosis via opsonization and 
the formation of C5 convertases is impaired by SAK and SCIN by cleavage of C3b and inhibition of the C3 
convertases, respectively. The impairment of C5 convertase formation will influence the cleavage of C5 to 
C5a and C5b, which will interfere the initiation of MAC and the chemoattraction via C5aR and C5a. This will 
inhibit the phagocytosis and lysis of bacteria. SSL7 impairs the cleavage of C5, which will have the same 
effects on chemoattraction and MAC. SSL5 prevents migration of neutrophils to the infected area by blocking 
PSGL-1 ultimately interfering phagocytosis. The killing of bacteria might be stimulated through the alternative 
pathway by increasing the hydrolysis of C3, which in hydrolysed form binds to CFB. The complex can then be 
cleaved by CFD, starting the pathway. Thus, the formation of C3 convertases might increase (Inspired by 
Rooijakkers et al., 2005).   
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Boost of the complement system 
Many of the mentioned S. aureus proteins have a directly or indirectly effect on the complement 
system and would therefore be an ideal pathway to boost in the immune system. The system 
contains many proteins, which can be targets for pharmaceutical interventions. Although it seems 
like an ideal target to boost, recent studies mostly describes complement-direct therapy that 
involves inhibition of proteins in the complement system.  It may be an advantage to upregulate the 
complement system during a MRSA infection, which could lead to an increase in killing of MRSA. 
One way to possibly boost the complement system is to see how the different pathways are 
activated and how to stimulate this activation. For example the alternative pathway is thought to 
be initiated by a spontaneous hydrolysis in the C3 protein thioester bond, which change it to a form 
of C3, called C3(H2O) that binds to the enzyme factor B (CFB). This complex is a substrate for the 
enzyme serine protease factor D (CFD) that cleaves the complex to the C3 convertase C3bBb. This 
convertase creates C3b from C3, which fully activates the alternative pathway (Fig. 11) (Noris & 
Remuzzi, 2013). Hence, a way to stimulate the activation of this pathway could be to stimulate the 
hydrolysis of C3, leading to increased formation of C3(H2O)Bb convertase. However, this could lead 
to a complication since a too increased level of C3 might result in an increased level of C3a, which is 
found in several diseases (Reis et al., 2015).  
The bindings of the antibodies IgG and IgM to the bacterial antigens initiate the classical pathway. 
Thus, an upregulation of the classical pathway might increase the level of IgG and IgM. A study by 
Moore et al. (2010) showed an engineered Fc portion of the IgG, which increased the affinity of the 
interaction between IgG and C1q, resulting in enhanced recruitment of the complement proteins 
and therefore an improved MAC activity (Moore et al., 2010). This particularly therapy might not be 
so efficient for MRSA infections, since SAK cleaves IgG and would thereby remove the engineered 
Fc portion of the IgG. If SAK only cleaves a specific type of IgG a solution to this problem could be to 
engineer those subclasses of IgG that SAK may not cleave, but further studies is required to 
determine what IgG types SAK cleaves. Another way to solve this problem might be to focus the 
study on engineering IgM instead of IgG, so a higher affinity between IgM and C1q might equal a 
reduced interaction between IgG and C1q. It might be possible to boost the classical pathway by 
engineering the antibody IgM, but it needs more research to see if this upregulation is possible and 
if this could lead to damage in the host. 
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The proteins secreted by S. aureus inhibit different parts in the complement system. Therefore, an 
increased activation of the classical and alternative pathway might not result in an enhanced killing 
of the bacteria. A solution to this problem might be to stimulate other proteins in the pathways. For 
example, the level of C5b could be increased by directly adding C5b and thereby avoid any of the 
mentioned S. aureus inhibitors. However, some of the S. aureus proteins that were not mentioned 
in this project might bind to or cleave C5b. Therefore, more research is needed in order to determine 
the most ideal target for upregulation of the complement system. 
A general concern with upregulation of the complement system is to disrupt the balance of 
regulation and activation, since it may lead to development of diseases. This is because a healthy 
complement system functions to maintain the host cells and tissues and as a protection against 
pathogens (Reis et al., 2015; Ricklin & Lambris, 2013). This indicates that if the homeostasis of the 
complement system is interfered, it may have consequences for the host tissues. Hence, any 
possible modification might need to be temporary, in order to maintain the homeostasis. 
The interference and boosting of TLR signaling  
As previously mentioned in this chapter, SSL3 may inhibit TLR signaling by binding to and inhibit 
TLR2 on human neutrophils and monocytes. The inhibition is maybe due to blocking the ligands, 
PAMPS, from binding to TLR2 or the dimerization of TLRs is prevented. When the mechanism of 
TLR2s are interfered, the signaling cascade that leads to the secretion of i.a. IL-1, IL-12, and TNF-α 
will not be initiated. TLR2 signaling leads also to secretion of IL-6 and IL-8 (Soboll et al., 2006) and 
this secretion may also be interfered. If the secretion of TNF-α, IL-1, and IL-6 is not initiated, the 
production of leukocytes and the activation of helper T-cells are impaired. In addition, reduced 
amounts of IL-1, IL-6, and IL-8 might inhibit the regulation of differentiation and growth of 
lymphocytes. An inhibited production of IL-12 may also affect the differentiation and growth of T-
cells. This interfering by SSL3 of TLR signaling can potentially be reduced. An experiment of Bardoel 
et al. (2012) indicates that the TLR2 inhibiting activity of SSL3 is located in the middle β-barrel 
domain of SSL3’s N-terminal, from amino acid 127 to 230 (Bardoel et al., 2012). Hence, maybe this 
location from amino acid 127 to 230 of the middle β-barrel can be cleaved or blocked so SSL3’s TLR2 
inhibitory activity can be prevented. This specific blocking of SSL3 activity might not have a high 
boosting effect on the immune system due to the many other factors that affect the system. The 
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interference of the TLR signaling might be reduced by LPS, because it enhance expression of IL-1, IL-
6, IL-8, IL-12 and TNF-α, when bound to CD14 or TLR4 in macrophages. Thus, with the addition of 
LPS the possible consequences of SSL3 might be neutralized by increasing these cytokines (Fig. 12). 
As described in the theory AKB-4924 increases the expression of HIF-1α, which induces expression 
of LL-37, VEGF, TNF-α, NO, IL-1β, IL-6 and IL-8, and the addition of this compound may also prevent 
the effect of SSL3. All the agents of AKB-4924 are also important in the inflammatory response and 
therefore AKB-4924 might be a potential pharmacological compound to boost the innate immune 
response against MRSA (Okumura et al., 2012). However, there may be side-effects by the use of 
AKB-4924 and LPS as boosters for the immune system.  
 
 
Fig. 12: The inhibition of TLR2 by SSL3 might impair the production of IL-1, IL-6, IL-8, IL-12, and TNF-α. This 
may lead to inference of leukocyte production, activation of helper T cells and the differentiation and growth 
of lymphocytes. The effects of SSL3 may be neutralized by LPS, which can increase the level of all the 
cytokines, and by AKB-4924 that can increase the level of IL-6, IL-8 and TNF-α. LPS stimulates the cytokine 
secretion via CD14 and TLR4 (Illustrated by Karoline Knudsen List, 2015).  
 
Cancer as a side-effect in treatment with AKB-4942 or LPS against MRSA 
Some of the agents that are upregulated by HIF-1α and LPS have other functions than supporting 
the inflammatory response. A study by Voronov et al. (2003) shows that IL-1 and especially IL-1β is 
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important in tumor blood vessel formation in some cancer cells in mice. Thus, IL-1β is essential to 
the development and growth of tumors in mice. This study also indicates that IL-1β is important for 
the tumor to spread and form lung metastases in mice (Voronov et al., 2003). If these findings are 
also valid for cancer cells in humans, it might be a disadvantage to treat MRSA infection with AKB-
4924 or LPS, since they upregulate IL-1 and thereby enhance tumor growth and spreading. Some of 
the other agents that are upregulated by HIF-1α and LPS does also have an impact on the formation 
of tumors. VEGF, TNF-α, NO, IL-1 and IL-8 regulate the tumor blood vessel formation and thus the 
growth of tumors. Furthermore, TNF-α, IL-1, IL-6 and IL-8 stimulate tumor development and 
migration (Pollard, 2004). The risk of getting cancer might be enhanced by treatment with AKB-4924 
or LPS, since they upregulate some of the agents that are important for tumor formation. Thus, it 
might not be appropriate to use either AKB-4924 or LPS as pharmacological compounds boosting 
the immune system against MRSA.   
 
Does LPS-induced macrophages have an effect on the killing of S. aureus?  
As mentioned LPS induces the expression of different cytokines that stimulate the macrophages to 
kill S. aureus. Thus, it was expected that the amount of S. aureus was lower in macrophages treated 
with LPS than in macrophages not treated with LPS. The results from the experiments slightly 
indicate (Fig. 10), that the amount of S. aureus was highest in the macrophages which are not 
treated with LPS irrespective of how long the macrophages has been infected with the bacteria. 
These results correspond to the hypothesis.  It was also expected that the amount of S. aureus would 
decrease when the time the macrophages had been exposed to LPS was longer, since LPS then had 
a longer time to stimulate the macrophages. In order to see whether the results are as expected, 
the p-values and the 95 % confidence interval were determined (Fig. 10; Table 3). 
The results (Table 3) of the infection time 0.5 hour, shows that there are significant differences 
(0.02<P<0.025) between the macrophages with the treatment -LPS compared to those treated with 
LPS2. Conversely, there is no difference between these two treatments when using the 95 % CI, 
because these overlap each other. In comparisons of -LPS with LPS24 the 95 % CI and the p-value 
(0.10 <P<0.20) indicate that there are no significant difference between the amounts of S. aureus. 
These results indicate that S. aureus are not killed by the LPS-induced macrophages after only 0.5 
hour.  
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When comparing the results of the infected macrophages after 2 hours infection, it is possible to 
see a significant difference (0.0005<P<0.005) between the macrophages, which have been treated 
with LPS2 or LPS24 compared to -LPS. These results show that the amount of S. aureus is decreased 
when LPS is added, which is consistent with the hypothesis describing that LPS stimulates the 
macrophages to enhance their killing of S. aureus.  
After 24 hours of infection there are not seen any significant difference (0.05<P<0.1) between -LPS 
and LPS2. This was not as expected and might be due to the macrophages have died, which would 
result in the lower amount of S. aureus that is observed in -LPS. The p-value (0.04 <P<0.05) indicates 
an uncertainty in the difference between -LPS and LPS24 after 24 hours of infection, which might 
indicate that LPS helps the macrophages to kill S. aureus. The 95 % CIs for -LPS and LPS24 did not 
show this difference.  
Generally at every harvest time there was not a difference (0.10 <P<0.20) between the macrophages 
that have been induced with LPS for 2 or 24 hours. This result is not as expected since it indicates 
that the time LPS stimulates the macrophages has no effect on the amount of S. aureus. This 
indicates that the macrophages do not need to be induced with LPS for a long period. In an 
experiment by Kopydlowski et al. (1999) the LPS response in macrophages was observed by 
measuring the expression of certain chemokines. LPS was added to the macrophages for among 
others 0.5, 2, 6 and 24 hours. The results showed that the expression of chemokines was induced 
already after 0.5 hours and then the expression was more enhanced after 2 hours and peaked at 6 
hours. Hereafter the expression began to decrease. It is indicated in their results that the expression 
of chemokines was almost the same at 2 hours and 24 hours (Kopydlowski et al., 1999). This 
tendency is also seen in our results, where there is no significant difference in the amount of S. 
aureus when treated with LPS for 2 and 24 hours.     
 
Furthermore, it was expected that when the infection time was increased, the macrophages had a 
longer time to kill S. aureus and therefore the amount of S. aureus was expected to be lower. The 
p-values (0.10 <P<0.20) showed that when the infection time increased from 0.5 to 2 hours and 0.5 
to 24 hours there was no significant difference in the amount of S. aureus, when treated with -LPS, 
LPS2 and LPS24. When the infection time was increased from 2 to 24 hours there was a significant 
difference (0.01 <P<0.02) in the amount of S. aureus, when treated with -LPS and LPS24, but there 
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was no difference (P<0.20) in treatment with LPS2. Conversely, the 95 % CIs showed no difference 
between any of the infection times in treatment with -LPS, LPS2 and LPS24. Thus, these results is 
not as expected since they indicate that the macrophages does not kill more S. aureus with a longer 
infection time.  
 
Optimization of experiment 
Some of the 95 % CIs contained negative values and they were therefore not reliable estimates. This 
is probably due to our experiment contained a small amount of observations, which increases the 
uncertainties of the calculated 95 % CIs and p-values. If the study had contained several more 
replicates, the data would be more reliable. Kopydlowski et al., (1999) showed that the peaking time 
for LPS-induced macrophages was at 6 hours. Thus, it could have been interesting to treat the 
macrophages with LPS for 6 hours to determine if more S. aureus have been killed compared to LPS2 
and LPS24. The low amount of S. aureus observed in the –LPS sample after infection with S. aureus 
for 24 hours compared to the amount after 0.5 and 2 hours, could be due to the macrophages have 
died. This part of the experiment can be optimized, by checking the amount of macrophages both 
before and after the harvest. Furthermore the experiment can also be optimized by testing whether 
LPS kills the macrophages. At last it is known that LPS-induced macrophages upregulates cytokines 
that stimulate the immune cells. The amount of cytokines can be measured in an extended 
experiment. 
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Conclusion  
When a healthy patient is infected with MRSA, S. aureus secretes proteins like SAK, SCIN, CHIPS, 
SSL3, SSL5, and SSL7. Chemotaxis, TLR signaling, MAC activation, and opsonization of the immune 
response is interfered by these proteins. This might impair the overall phagocytosis and lysis of S. 
aureus. The complement system would be an ideal target to boost, since most of these proteins 
affect this system. However, there are no studies about the upregulating of the complement system 
and therefore further studies are needed. In addition, a disruption in the balance of regulation and 
activation in the complement system may lead to development of diseases and interference of the 
homeostasis if the boosting of the system is too intense. Another potential way to boost the immune 
system is with the compounds AKB-4924 and LPS. However, treatment with these might have severe 
consequences as cancer, and therefore further studies are needed before these compounds can be 
used as treatments against MRSA. Based on our experiment it is possible to conclude, that LPS is 
able to stimulate the macrophages to kill S. aureus at the harvest time 2 hours. At the harvest times 
0.5 and 24 hours, it is not possible to conclude whether LPS stimulates the macrophages to kill S. 
aureus. The bacterial killing by macrophages are not increased or decreased  when induced with LPS 
for 2 or 24 hours. This applies also to the infection time of S. aureus, where the amount of killed S. 
aureus is not significant chanced with an increase in infection time. These results are based on a low 
amount of collected data, which decrease the reliability of the results, and therefore further 
experiments might give a more reliable indication of whether LPS-induced macrophages increase 
their killing of S. aureus. 
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Appendix  
Data collected from the first week of experiment  
The four tables represent the raw data. The first table shows the negative control for the undiluted 
treatment. Furthermore, the counted amount of S. aureus, in CFU, for the macrophages for –LPS, 
LPS2 and LPS24 at the different harvest times is shown. The red numbers indicate, that the amount 
of S. aureus was too small to include in the statistical analysis.  
 
100 Negative control 
 0 0 0 0 
 
10-1 
Harvest time 
(hours) wells - LPS LPS2 LPS24 
 0.5 A 28 24 26 27 9 9 18 30 10 5 6 11 
 B 23 21 27 22 5 5 14 10 7 7 8 9 
 2 A 24 31 34 25 6 9 2 3 7 6 7 6 
 B 25 38 41 18 8 7 2 8 9 10 6 4 
 24 A   7 4 8   3 6 2   0 2 1 
 B   11 9 10   1 0 0   2 2 1 
 
10-2 
Harvest time 
(hours) wells - LPS LPS2 LPS24 
 0.5 A 2 0 5 4 2 0 0 0 1 1 1 0 
 B 3 4 2 8 1 1 2 2 1 2 1 4 
 2 A 3 3 1 1 1 1 1 1 1 1 0 0 
 B 1 5 2 2 0 0 0 0 1 0 0 0 
 24 A  1 1 1  0 0 0  1 0 0 
 B   3 1 1   1 0 1   0 0 0 
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10-3 
Harvest time 
(hours) wells - LPS LPS2 LPS24 
 0.5 A 0 1 0 2 0 0 2 0 0 0 0 0 
 B 2 0 1 0 0 0 1 0 0 1 1 0 
 2 A 0 1 0 0 0 0 0 0 0 0 1 1 
 B 0 0 1 0 1 0 0 0 1 0 0 0 
 24 A   1 0 0   0 3 2   0 0 0 
 B   0 0 0   0 0 0   0 0 0 
 
The next three tables show the average amount of S. aureus for each well, for the three different 
dilutions. The x indicates that there was too few data to calculate the average amount of S. aureus.  
10-1 Time (hours) Well -LPS (CFU) LPS2 (CFU) LPS24 (CFU) 
 
0.5 
A 26.25 16.5 8 
 B 23.25 8.5 7.75 
 
2 
A 28.5 6 6.5 
 B 30.5 7.67 7.25 
 
24 
A 6.33 4.5 x 
 B 10 x x 
 
10-2 Time (hours) Well -LPS (CFU) LPS2 (CFU) LPS24 (CFU) 
 
0.5 
A 4.5 x x 
 B 5 x 4 
 
2 
A 3 x x 
 B 5 x x 
 
24 
A x x x 
 B 3 x x 
 
 
51/62 
 
10-3 Time (hours) Well -LPS (CFU) LPS2 (CFU) LPS24 (CFU) 
 0.5 A x x x 
 B x x x 
 2 A x x x 
 B x x x 
 24 A x x x 
 B x x x 
 
The next three tables show the average amount of S. aureus in CFU/ml, for the three different 
dilutions. The x indicates that there was too few data to calculate the average amount of S. aureus.  
10-1 Time (hours) 
-LPS 
(CFU/ml) 
LPS2 
(CFU/ml) 
LPS24 
(CFU/ml) 
 0.5 24750 12500 7875 
 2 29500 6833.33 6875 
 24 8166.67 4500.00 x 
 
10-2 Time (hours) 
-LPS 
(CFU/ml) 
LPS2 
(CFU/ml) 
LPS24 
(CFU/ml) 
 0.5 47500 x 40000 
 2 40000 x x 
 24 30000 x x 
 
10-3 Time (hours) 
-LPS 
(CFU/ml) 
LPS2 
(CFU/ml) 
LPS24 
(CFU/ml) 
 0.5 x x x 
 2 x x x 
 24 x x x 
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The table represents the total average amount of S. aureus measured in CFU/ml. The x indicates 
that there was too few data to calculate the total average amount of S. aureus.  
 
 
 
 
 
 
Data collected from the second week of experiment  
The four tables represent the raw data. The first table includes the negative control for the undiluted 
treatment. Furthermore, the counted amount of S. aureus, in CFU, for the macrophages for –LPS, 
LPS2 and LPS24 at the different harvest times is shown. The red numbers indicate, that the amount 
of S. aureus was too small to include in the statistical analysis. The red x indicates that the amount 
of S. aureus were too high to count. 
 
100 
Harvest 
time 
(hours) wells 
Negative 
control - LPS LPS2 LPS24 
 0.5 A 0 0 0 0 56 37 45 54 13 16 17 18 11 12 6 9 
 B 0 0 0 1 x x x x 15 14 13 14 43 43 46 46 
 2 A 0 0 0 0 x x x x 7 8 8 6 29 41 42 47 
 B 0 0 0 0 x x x x 12 7 20 17 38 36 45 39 
 24 A 0 0 0 0 71 55 53 45 36 47 41 34 22 21 25 17 
 B 0 0 0 0 28 45 38 48 7 8 3 1 15 17 20 20 
 
Total average  Time (hours) 
-LPS 
(CFU/ml) 
LPS2 
(CFU/ml) 
LPS24 
(CFU/ml) 
 0.5 36125 12500 23937.50 
 2 34750 6833.33 6875 
 24 19083.33 4500 x 
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10-1 
Harvest 
time 
(hours) wells - LPS LPS2 LPS24 
 0.5 A 16 17 27 19 4 0 3 0 2 6 4 6 
 B 18 16 16 12 2 6 1 1 5 7 5 8 
 2 A 16 17 26 19 1 2 0 0 13 7 8 5 
 B 14 15 15 11 0 3 1 3 11 3 5 1 
 24 A 12 14 5 8 8 3 2 1 3 2 3 2 
 B 7 12 6 5 2 1 1 0 3 4 3 1 
 
10-2 
Harvest 
time 
(hours) wells - LPS LPS2 LPS24 
 0.5 A 2 2 3 1 3 1 1 0 1 0 0 1 
 B 7 3 4 2 0 0 0 0 0 0 2 2 
 2 A 2 4 2 0 0 0 0 0 0 2 0 0 
 B 0 1 4 0 0 0 0 0 0 0 0 1 
 24 A 1 0 0 1 1 0 0 1 0 0 0 0 
 B 0 0 0 1 0 0 0 0 0 0 1 1 
 
The next three tables show the average amount of S. aureus in CFU, for the three different dilutions. 
The x indicates that there was too few data to calculate the average amount of S. aureus.  
100 Time (hours) Well -LPS (CFU) LPS2 (CFU) LPS24 (CFU) 
 
0.5 
A 48 16 9.5 
 B x 14 44.5 
 
2 
A x 7.25 39.75 
 B x 14 39.5 
 
24 
A 56 39.5 21.25 
 B 39.75 6 18 
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10-1 Time (hours) Well -LPS (CFU) LPS2 (CFU) LPS24 (CFU) 
 
0.5 
A 19.75 3.5 5.33 
 B 15.5 6 6.25 
 
2 
A 19.5 X 8.25 
 B 13.75 3 6.33 
 
24 
A 9.75 5.5 3 
 B 7.5 x 3.33 
 
 
10-2 Time (hours) Well -LPS (CFU) LPS2 (CFU) LPS24 (CFU) 
 
0.5 
A 3 x x 
 B 4.67 x x 
 
2 
A 4 x x 
 B 4 x x 
 
24 
A x x x 
 B x x x 
 
The next three tables show the average amount of S. aureus in CFU/ml, for the three different 
dilutions. The x indicates that there was too few data to calculate the average amount of S. aureus.  
100 Time (hours) 
-LPS 
(CFU/ml) 
LPS2 
(CFU/ml) 
LPS24 
(CFU/ml) 
  0.5 4800 1500 2700 
  2 x 1062.5 3962.5 
  24 4787.5 2275 1962.5 
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10-1 Time (hours) 
-LPS 
(CFU/ml) 
LPS2 
(CFU/ml) 
LPS24 
(CFU/ml) 
  0.5 17625 4750 5791.67 
  2 16625 3000 7291.67 
  24 8625 5500 3166.67 
 
10-2 Time (hours) 
-LPS 
(CFU/ml) 
LPS2 
(CFU/ml) 
LPS24 
(CFU/ml) 
  0.5 38333.33 x x 
  2 40000 x x 
  24 x x x 
 
The table represents the total average amount of S. aureus measured in CFU/ml. The x indicates 
that there was too few data to calculate the total average amount of S. aureus.  
Total 
average  Time (hours) 
-LPS 
(CFU/ml) 
LPS2 
(CFU/ml) 
LPS24 
(CFU/ml) 
  0.5 20252.78 3125 4245.83 
  2 28312.50 2031.25 5627.08 
  24 6706.25 3887.50 2564.58 
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95 % CI for the whole data set  
The table shows the sum of the averages of the total amount of S. aureus for both experiments. 
 
 
 
 
 
The tables below contain standard deviations (SD), standard error of the mean (SE), degrees of 
freedom (df), which are used to find the table t-value. At last the calculated SE is multiplied by the 
table t-value (SE*t) to determine the 95 % CI. 
 
 
 
 
 
 
df Time (hours) -LPS LPS2 LPS24 
 0.5 4 2 3 
 2 4 2 2 
 24 4 2 2 
 
 
Total 
average  Time (hours) 
-LPS 
(CFU/ml) 
LPS2 
(CFU/ml) 
LPS24 
(CFU/ml) 
  0.5 28188.89 7812.50 14091.67 
  2 31531.25 4432.29 6251.04 
  24 12894.79 4193.75 2564.58 
SD Time (hours) -LPS LPS2 LPS24 
 0.5 16835.19 5651.33 17402.57 
 2 11101.98 2936.86 1813.82 
 24 11531.16 1650.82 851.47 
SE Time (hours) -LPS LPS2 LPS24 
 0.5 7528.92 3262.80 8701.29 
 2 4964.96 1695.60 1047.21 
 24 5156.89 953.10 491.60 
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t Time (hours) -LPS LPS2 LPS24 
 0.5 2.78 4.3 3.18 
 2 2.78 4.3 4.3 
 24 2.78 4.3 4.3 
 
SE*t Time (hours) -LPS LPS2 LPS24 
 0.5 20900.3 14039.81 27687.5 
 2 13782.72 7296.15 4506.14 
 24 14315.52 4101.2 2115.35 
 
The two tables show the upper and lower bound of the 95 % CIs.   
95 % CI upper bound Time (hours) -LPS LPS2 LPS24 
 0.5 49089.19 21852.31 41779.17 
 2 45313.97 11728.44 10757.18 
 24 27210.31 8294.95 4679.93 
 
95 % CI lower bound Time (hours) -LPS LPS2 LPS24 
 0.5 7288.59 -6227.31 -13595.83 
 2 17748.53 -2863.86 1744.90 
 24 -1420.73 92.55 449.23 
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P-values of LPS treatments 
The five tables contain the difference in the total average for both experiments (y1-y2), the SE of 
these differences (SEy1-y2), the calculated t-test, the df and at last the table p-value.  
y1-y2 Time (hours) (-LPS)-LPS2 (-LPS)-LPS24 LPS24-LPS2 
 0.5  20376.39 14097.22 6279.17 
 2  27098.96 25280.21 1818.75 
 24  8701.04 10330.21 1629.17 
 
 
SEy1-y2 Time (hours) (-LPS)-LPS2 (-LPS)-LPS24 LPS24-LPS2 
 0.5  8205.52 11506.39 9292.91 
 2 5246.51 5074.19 1992.91 
 24 5244.23 5180.27 1072.41 
 
t Time (hours) (-LPS)-LPS2 (-LPS)-LPS24 LPS24-LPS2 
 0.5  2.48 1.23 0.68 
 2  5.17 4.98 0.91 
 24  1.66 1.99 1.52 
 
df Time (hours) (-LPS)-LPS2 (-LPS)-LPS24 LPS24-LPS2 
 0.5  6 7 5 
 2 6 6 4 
 24  6 6 4 
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p-values Time (hours) (-LPS)-LPS2 LPS24-(-LPS) LPS24-LPS2 
 0.5 0.020<P<0.025 0.10<P<0.20 P>0.20 
 2 0.0005<P<0.005 0.0005<P<0.006 P>0.20 
 24 0.05<P<0.10 0.04<P<0.05 0.10<P<0.20 
 
P-values of the comparison of the harvest times  
The five tables contain the difference in the total average for both experiments (y1-y2), the SE of 
these differences (SEy1-y2), the calculated t-test, the df and at last the table p-value.  
 
y1-y2  0.5 - 2 hours 0.5 - 24 hours 2 - 24 hours 
 -LPS 3342.36 15294.10 18636.46 
 LPS2 3380.21 3618.75 238.54 
 LPS24 7840.63 11527.09 3686.46 
 
SEy1-y2  0.5 - 2 hours 0.5 - 24 hours 2 - 24 hours 
 -LPS 9018.62 9125.7 7158.51 
 LPS2 3677.08 3399.15 1945.11 
 LPS24 8764.08 8715.16 1156.86 
 
t  0.5 - 2 hours 0.5 - 24 hours 2 - 24 hours 
 -LPS 0.37 1.68 2.60 
 LPS2 0.92 1.06 0.12 
 LPS24 0.89 1.32 3.19 
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df  0.5 - 2 hours 0.5 - 24 hours 2 - 24 hours 
 -LPS 8 8 8 
 LPS2 4 4 4 
 LPS24 5 5 4 
 
p-value  0.5 - 2 hours 0.5 - 24 hours 2 - 24 hours 
 -LPS P>0.20 0.10<P<0.20 0.01<P<0.02 
 LPS2 P>0.20 0.10<P<0.20 P>0.20 
 LPS24 P>0.20 0.10<P<0.20 0.01<P<0.02 
 
Example of calculations  
First, the SD is calculated. This indicates the variation of the dataset:  
𝑆𝐷 =  √
∑(𝑌𝑖 − ?̅?)2
𝑛 − 1
 
 Yi is the amount of CFU/ml for the specific harvest time. Ȳ is the average of CFU/ml to the same 
harvest time and n is the number of observations. Example of SD for -LPS after 0.5 hour:  
𝑆𝐷 =  √
∑(24750 − 20252.78)2 + (47500 − 20252.78)2 + (4800 − 20252.78)2 + (17625 − 20252.78)2 + 3888.33 − 20252.78)2
5 − 1
= 16835.19 𝑐𝑓𝑢/𝑚𝑙 
SD is used to calculate the SE also called the standard error of the mean. It is an estimate of the 
sample mean compared to the mean of the population: 
𝑆𝐸 =  
𝑆𝐷
√𝑛
 
SD is the standard deviation and n is the number of observations. Example of SE for -LPS after 0.5 
hour:  
𝑆𝐸 =  
16835.19
√5
= 7528.92  
Afterwards the SE of the differences between the values (ȳ1-ȳ2) is calculated:  
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𝑆𝐸(𝑌1−𝑌2) = √
𝑆𝐷𝑌1
2
𝑛𝑌2
+
𝑆𝐷𝑌2
2
𝑛𝑌2
 
Example of 𝑆𝐸(𝑌1−𝑌2)for -LPS and LPS2 after 0.5 hour: 
𝑆𝐸((−𝐿𝑃𝑆)0.5  −𝐿𝑃𝑆20.5) =  √
1683.192
5
+
5651.332
3
= 8205.52 𝐶𝐹𝑈/𝑚𝑙 
 
𝑆𝐸(𝑌1−𝑌2) is used in the statistical analysis, t-test. The t-test shows if there is a significant difference 
between the two mean of the data sets: 
𝑡 =  
𝑌1 − 𝑌2
𝑆𝐸(𝑌1−𝑌2)
 
Y1 and Y2 are the means of two different treatments at the same harvest time. Example of t for -LPS 
and LPS2 after 0.5 hour: 
𝑡 =
28188.89 − 7812.50
8205.52
= 2.48   
 
The calculated t is compared with the t-table, but first the df is determined, by adding the number 
of observations n for –LPS, LPS2 or LPS24, respectively.  
𝑑𝑓 = 𝑛𝑌1 + 𝑛𝑌2 − 2  
 
𝑑𝑓 =  5−𝐿𝑃𝑆0.5 + 3𝐿𝑃𝑆20.5 − 2 =  6 
The p-value is determined from a p-value table. Both the t and df are read, and a specific p-value 
can be determined. With this value, it can be estimated if there is a significant difference between 
the two samples.  
 
 
62/62 
 
The 95 % CI 
The 95 % CI is calculated to indicate with a 95 % certainty that the populations’ mean is in this 
interval and shows the reliability of the dataset. 
95 % 𝐶𝐼 = 𝑌𝑖 ± 𝑆𝐸 ∙ 𝑡 
Yi is the mean of one of the treatments at a specific harvest time. SE has been calculated earlier and 
t is found in a statistical table with the use of df. 
𝑑𝑓 = 𝑛 − 1 
An example of 95 % CI for –LPS at 0.5 hour:  
95 % 𝐶𝐼−𝐿𝑃𝑆 0.5 = 28188.89 ± 7528.92 ∙ 2.776 = (4908.19; 7288.59) 
 
 
